[1]殷梦杰,沈建东.肿瘤负荷评分在TACE联合微波消融治疗肝细胞肝癌预后中的预测价值[J].介入放射学杂志,2025,34(08):865-870.[doi:10.3969/j.issn.1008-794X.2025.08.012 ]
　YIN Mengjie,SHEN Jiandong..The predicting value of tumor burden score in transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma[J].J Intervent Med,2025,34(08):865-870.[doi:10.3969/j.issn.1008-794X.2025.08.012 ]
点击复制

肿瘤负荷评分在TACE联合微波消融治疗肝细胞肝癌预后中的预测价值 ()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年08
页码:
865-870
栏目:
临床研究
出版日期:
2025-08-25

文章信息/Info

Title:
The predicting value of tumor burden score in transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma
文章编号:
1008-794X(2025)-008-0865-06
作者:
殷梦杰;  沈建东
226001 江苏南通 南通大学附属南通第三医院(南通市第三人民医院)介入血管科
Author(s):
YIN Mengjie; SHEN Jiandong.
Department of Vascular Intervention,Affiliated Nantong Third Hospital of Nantong University(Nantong Municipal Third People's Hospital),Nantong,Jiangsu Province 226001,China
关键词:
肝细胞癌;  肝动脉化疗栓塞;  微波消融;  肿瘤负荷评分;  预后
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2025.08.012
文献标志码:
B
摘要:
目的 探讨肿瘤负荷评分(tumor burden score,TBS)在肝动脉化疗栓塞(TACE)联合微波消融(microwave ablation,MWA)治疗早中期肝细胞癌(HCC)患者预后的预测价值。方法 回顾性分析2013年1月至2019年12月79例在南通大学附属南通第三医院介入科接受TACE联合MWA治疗的HCC患者临床资料。采用时间依赖的ROC曲线及曲线下面积(area under the ROC curve,AUC)评价TBS(TBS2=肿瘤最大径2+肿瘤数目2)在5年生存率和无瘤生存率中预测的准确性。根据K-Means法选取TBS最佳截断值,将HCC患者分成3组作生存分析。Cox多因素分析筛选出影响接受TACE联合MWA治疗的HCC患者预后的独立因素。结果 ROC曲线统计显示TBS预测HCC患者经TACE联合MWA治疗后5年生存率的AUC最优,为0.815,肿瘤最大直径的AUC为0.684,肿瘤数目的AUC为0.640。根据最佳截断值,将79例HCC患者分成3组:TBS≤1.9( n =34,43.1%); 1.9<TBS≤3.3( n =25,31.6%); TBS>3.3( n =20,25.3%)。作生存分析显示,TBS≤1.9组的5年总生存率为76.5%,1.9<TBS≤3.3组56.7%,TBS>3.3组6.3%,随着TBS值的升高,患者的5年生存率逐渐下降。3组之间5年生存率比较差异具有统计学意义( P <0.05)。3组间无瘤生存率比较差异也具有统计学意义( P <0.05),且随着TBS值的升高,无瘤生存率逐步降低。多因素分析显示,TBS是影响HCC患者接受TACE联合MWA治疗后的总生存率和无瘤生存率的独立因素。结论 TBS对预测接受TACE联合MWA治疗的HCC患者的预后具有较好的效能。

参考文献/References:

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71:209-249.
[2]Petrick JL,Kelly SP,Altekruse SF,et al.Future of hepatocellular carcinoma incidence in the United States forecast through 2030[J].J Clin Oncol,2016,34:1787-1794.
[3]郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46:221-231.
[4]《原发性肝癌诊疗指南(2024年版)》编写专家委员会.原发性肝癌诊疗指南(2024年版)[J].中国临床医学,2024,31:277-334.
[5]Sasaki K,Morioka D,Conci S,et al.The tumor burden score:a new “metro-ticket” prognostic tool for colorectal liver metas-tases based on tumor size and number of tumors[J].Ann Surg,2018,267:132-141.
[6]陶 杰,史政荣.联合卡瑞利珠单抗和仑伐替尼的肝动脉灌注化疗与肝动脉化疗栓塞对不可切除肝细胞癌的疗效对比[J].重庆医学,2023,52:2758-2763.
[7]姆尼热·阿卜力米提,陈亚杰,汤旭山,等.TBS和放疗后AFP稳定时间对肝细胞癌合并PVTT患者预后的影响[J].中华放射肿瘤学杂志,2024,33:719-725.
[8]Xia C,Dong X,Li H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chin Med J(Engl),2022,135:584-590.
[9]Zhou J,Sun H,Wang Z,et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma(2019 edition)[J].Liver Cancer,2020,9:682-720.
[10]Vogl TJ,Freichel J,Gruber-Rouh T,et al.Interventional oncological treatment of hepatocellular carcinoma(HCC)-a single-center long-term evaluation of thermoablation techniques like LITT,MWA,and TACE in a multimodal application over 26 years[J].Heliyon,2023:e14646.
[11]丁 丁,付守忠,戴 锋,等.介入联合索拉菲尼治疗肝癌伴门脉癌栓的疗效观察[J].中国医学计算机成像杂志,2023,29:433-437.
[12]Prince D,Liu K,Xu W,et al.Management of patients with intermediate stage hepatocellular carcinoma[J].Ther Adv Med Oncol,2020,12:1758835920970840.
[13]Wang Q,Xia D,Bai W,et al.Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:a multicentre observational study[J].J Hepatol,2019,70:893-903.
[14]Mehta N,Bhangui P,Yao F,et al.Liver transplantation for hepatocellular carcinoma.working group report from the ILTS transplant oncology consensus conference[J].Transplan-tation,2020,104:1136-1142.
[15]Ho SY,Liu PH,Hsu CY,et al.Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation:role of albumin-bilirubin(ALBI)grade vs easy ALBI grade[J].Expert Rev Gastroenterol Hepatol,2022,16:903-911.
[16]史逸恺,倪才方.TACE治疗肝癌后总生存期的替代终点研究进展[J].介入放射学杂志,2022,31:728-732.
[17]郝晓光,李伟靖,朱丽娜,等.中晚期肝癌患者经导管化疗栓塞治疗后序贯射频消融手术治疗时机的选择[J].介入放射学杂志,2022,31:908-912.
(收稿日期:2024-07-17)
(本文编辑:茹 实)

相似文献/References:

[1]郭丽萍,张晓玲,王莉娜.经导管肝动脉化疗栓塞联合高强度聚焦超声治疗原发性肝癌的护理[J].介入放射学杂志,2010,(04):328.
　GUO Liping,ZHANG Xiaoling,WANG Lina.The nursing care for patients of hepatocellular carcinoma treated with transcatheter hepatic arterial chemoembolization and high intensive focus ultrasound[J].J Intervent Med,2010,(08):328.
[2]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
　SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].J Intervent Med,2010,(08):382.
[3]池嘉昌,沈加林,许建荣,等.全肝CT灌注成像在原发性肝癌TACE术后局部病灶活性评估中的临床应用[J].介入放射学杂志,2010,(07):540.
　CHI Jiachang,SHEN Jialin,XU Jianrong,et al.Clinical application of whole－liver perfusion－enhanced CT imaging in evaluating the activity of residual hepatocellular carcinoma after TACE[J].J Intervent Med,2010,(08):540.
[4]翁志成,杨维竹,江娜,等.CT引导下１２５I放射性粒子植入治疗肝癌门静脉癌栓的疗效评价[J].介入放射学杂志,2010,(07):535.
　WENG Zhicheng,YANG Weizhu,JIANG Na,et al.Evaluation of CT－guided１２５I seed implantation combined with transcatheter arterial chemoem－bolization in treating portal vein tumor thrombus associated with hepatocellular carcinoma[J].J Intervent Med,2010,(08):535.
[5]王悍 王精兵 张贵祥 王麟川.肝细胞癌动脉化疗栓塞术后并发脑梗死一例[J].介入放射学杂志,2005,(04):442.
　WANG Han WANG Jing-bing ZHANG Gui-xiang WANG Lin-chuan.Cerebral infarction aften transaterial shemoembolization for hepatocellular carcinoma a cage report[J].J Intervent Med,2005,(08):442.
[6]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[7]程洁敏,王建华.喜树碱微球化疗栓塞治疗原发性肝癌10例报告[J].介入放射学杂志,1993,(01):47.
[8]欧阳墉,马和平,张学军,等.肝细胞癌的鉴别诊断——附10例分析[J].介入放射学杂志,1996,(01):40.
[9]杨永波,程红岩.肝动脉化疗栓塞治疗中碘油用量的现状与研究进展[J].介入放射学杂志,2012,(04):348.
　.Ｔｈｅ ｖｏｌｕｍｅ ｏｆ Ｌｉｐｉｏｄｏｌ ｕｓｅｄ ｉｎ ＴＡＣＥ： ｉｔｓ ｃｕｒｒｅｎｔ ｓｉｔｕａｔｉｏｎ ａｎｄ ｒｅｓｅａｒｃｈ ｐｒｏｇｒｅｓｓ [J].J Intervent Med,2012,(08):348.
[10]周斌,李征然,钱结胜,等.原发性肝癌肝移植后肿瘤复发的化疗栓塞治疗[J].介入放射学杂志,2009,(03):185.
　ZHOU Bin,LI Zhengran,QIAN Jiesheng,et al.Chemoembolization for recurrent hepatocellular carcinoma after liver transplantation[J].J Intervent Med,2009,(08):185.
[11]杨 俊,李璐阳,李浩铭,等.肝动脉化疗栓塞联合靶向及免疫治疗对中晚期肝细胞癌的疗效[J].介入放射学杂志,2025,34(04):398.[doi:10.3969/j.issn.1008-794X.2025.04.011]
　YANG Jun,LI Luyang,LI Haoming,et al.Efficacy of transarterial chemoembolization combined with targeted therapy and immunotherapy in treating advanced hepatocellular carcinoma[J].J Intervent Med,2025,34(08):398.[doi:10.3969/j.issn.1008-794X.2025.04.011]

备注/Memo

备注/Memo:
基金项目: 北京肝胆相照公益基金会临床科研专项资助基金(GDXZ-08-20); 江苏省卫生健康委员会科研基金(Z2022054)
通信作者: 沈建东 E-mail:shenjiandong_78722@hotmail.com
更新日期/Last Update: 2025-08-25